Form 8-K - Current report:
SEC Accession No. 0000950170-24-120188
Filing Date
2024-11-04
Accepted
2024-11-01 18:05:42
Documents
12
Period of Report
2024-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apvo-20241101.htm   iXBRL 8-K 42567
2 EX-4.1 apvo-ex4_1.htm EX-4.1 34191
  Complete submission text file 0000950170-24-120188.txt   198226

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apvo-20241101.xsd EX-101.SCH 26037
14 EXTRACTED XBRL INSTANCE DOCUMENT apvo-20241101_htm.xml XML 4925
Mailing Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121
Business Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121 206-838-0500
Aptevo Therapeutics Inc. (Filer) CIK: 0001671584 (see all company filings)

EIN.: 811567056 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37746 | Film No.: 241420278
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)